52/18. Glasdegib- (DAURISMO)- (Nov 2018)- to treat newly diagnosed acute myeloid(AML) in adult patients
Drug Name:
52/18. Glasdegib- (DAURISMO)- (Nov 2018)- to treat newly diagnosed acute myeloid(AML) in adult patients
List Of Brands:
Indication Type Description:
Indication:
U.S. FDA APPROVED DRUGS DURING 2018
Sr.No- 52
Name of the Drug- DAURISMO
Active Ingredient - Glasdegib
Pharmacological Classification-
To treat newly disgnosed acute myeloid leukemia(AML)- in adult patients
Date of Approval - 11/21/2018
(Ref- FDA approved List 2018)
